HemoDefend Information

HemoDefend is transforming transfusion medicine with a simple yet powerful mission — to make blood universally compatible, readily available, and safer for all patients. Our patented HemoDefend™ filter is a gravity-driven, single-use device that works in under 15 minutes with plasma, platelets, or whole blood. It requires no power or specialized equipment, and effectively removes anti-A and anti-B blood group antibodies while preserving critical coagulation factors. The result: low-titer “universal” blood products that can be used for anyone, anywhere — including in pre-hospital, trauma, and military settings. By simplifying blood logistics and enabling the production of universal plasma and platelets, HemoDefend helps blood centers and hospitals reduce waste, improve supply reliability, and accelerate emergency transfusions when every second counts. The platform is designed for broad compatibility, including use with freeze-dried plasma, and offers a scalable path to universal plasma, platelets, and whole blood — all from existing donor inventory. HemoDefend has been supported by over $16 million in non-dilutive funding and developed in collaboration with leading institutions such as UK NHS Blood & Transplant (NHSBT), with strong interest from U.S. government agencies including BARDA. The program is advancing toward regulatory clearance in the U.S. and Europe. Our team combines deep expertise in blood purification, transfusion medicine, and medical device innovation, backed by a proven track record of clinical translation and commercialization. At HemoDefend, we’re redefining what’s possible in transfusion care — unlocking the full potential of the blood supply to save more lives, in more places, every day.